Built for Today.
Engineered for 2026.
Abiozen is built with a clear, phased growth strategy—designed to deliver immediate value while methodically expanding into advanced clinical and manufacturing capabilities.
Transparent Roadmap Philosophy
We communicate our long-term vision transparently, without premature commitments. All future capabilities are under structured evaluation and development planning.
Readiness Prerequisites
Phased Growth Strategy
A deliberate, phased approach to platform evolution, ensuring stability and compliance at each stage of growth.
Platform Foundation
Scientific distribution, independent quality control, and early-stage clinical services.
Key Capabilities
-
Independent QC
U.S.-based lab with digital CoA verification
-
Clinical Services
CRO360™ protocol and research enablement
Mid-2026: Clinova AI™
Introduction of electronic data capture and clinical data infrastructure supporting scalable research programs.
2026+: Manufacturing
Advanced R&D capabilities including lyophilization, crystallization, and sterile injectable API manufacturing.
Future capabilities are under structured development and will be introduced in alignment with regulatory readiness.